News
KRRO
12.70
+4.36%
0.53
Weekly Report: what happened at KRRO last week (0615-0619)?
Weekly Report · 5d ago
Korro Bio: RNA Editor Plots Way Back After AATD Study Fail - I'm Holding
Seeking Alpha · 06/15 18:02
Weekly Report: what happened at KRRO last week (0608-0612)?
Weekly Report · 06/15 09:36
Korro Bio Stockholders Approve Directors, Pay and Auditor
TipRanks · 06/11 22:00
Korro Bio shareholders elect Bermingham, Meyers as Class I directors at annual meeting
PUBT · 06/11 20:43
Weekly Report: what happened at KRRO last week (0601-0605)?
Weekly Report · 06/08 09:34
Korro Bio director Jean Francois Formela disposes of 2,860 common shares worth $39,897‬
PUBT · 06/01 21:35
Weekly Report: what happened at KRRO last week (0525-0529)?
Weekly Report · 06/01 09:36
Korro Bio initiated with an Outperform at LifeSci Capital
TipRanks · 05/29 10:15
Analysts Are Bullish on Top Healthcare Stocks: Korro Bio (KRRO), Veeva Systems (VEEV)
TipRanks · 05/28 14:20
Korro Bio CEO Ram Aiyar to present at Jefferies Global Healthcare Conference
PUBT · 05/27 11:03
Korro Bio (KRRO) Receives a Buy from H.C. Wainwright
TipRanks · 05/26 17:45
Weekly Report: what happened at KRRO last week (0518-0522)?
Weekly Report · 05/25 09:38
Korro Bio To Advance KRRO-111 As Potential Treatment For AATD
NASDAQ · 05/20 15:09
Korro Bio Advances KRRO-111 for Alpha-1 Deficiency
TipRanks · 05/19 11:37
Korro Bio Announces Addition Of KRRO-111 For Potential Treatment Of AATD To Pipeline Of Therapeutic Programs In Development
Benzinga · 05/19 11:17
Korro Bio selects KRRO-111 RNA-editing candidate for alpha-1 antitrypsin deficiency
PUBT · 05/19 11:03
Korro Bio Price Target Cut to $15.00/Share From $20.00 by HC Wainwright & Co.
Dow Jones · 05/19 10:31
Korro Bio Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 05/19 10:31
HC Wainwright & Co. Maintains Buy on Korro Bio, Lowers Price Target to $15
Benzinga · 05/19 10:21
More
Webull provides a variety of real-time KRRO stock news. You can receive the latest news about Korro Bio, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About KRRO
Korro Bio, Inc. is a clinical-stage biopharmaceutical company. The Company discovers, develops, and commercializes genetic medicines based on editing ribonucleic acid (RNA), enabling treatment of both rare and highly prevalent diseases. The Company is generating a portfolio of differentiated programs that are designed to harness the body’s natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, it is expanding the reach of genetic medicines. Using its oligonucleotide-based approach, the Company brings its medicines to patients by leveraging its proprietary platform. The Company’s first development candidate, KRRO-110, is in development as a potential treatment for Alpha-1 Antitrypsin Deficiency (AATD) that has the potential to be disease-modifying and provide a differentiated therapeutic option.